Lausanne, Switzerland –June 7, 2013 – Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm and including Neomed and Initiative Capital Romandie. The funds will be used to help Diagnoplex obtain CE marking (European Conformity) for Colox, a non-invasive blood-based test for the early detection of colon cancer. The company also wishes to prepare a comparative clinical trial with the screening test that should allow for patient reimbursement.
